Efforts are underway to standardize pharmacogenetic testing, but experts say more needs to be done to encourage broader acceptance of these recommendations.
Companies said at AACC that as labs grow larger, they see growth in demand for integrated, modular systems that help customers manage complexity and costs.
Physicians can now use the Dako PD-L1 IHC 22C3 pharmDx assay to identify urothelial carcinoma patients who may benefit from the anti-PD1 immunotherapy.
The BD Rhapsody Single-Cell Analysis System empowers and streamlines single-cell research with a complete system of tools, including reagents and analysis software, that work together to meet neuroscience experimental needs. Neuroscientists’ ability to identify and characterize individual cells in the nervous system opens the door to finding pathogenic cells, regenerative cells, and pathways that drug manufacturers can exploit for the discovery of therapeutics for neurodegenerative disease.
BBI has developed Morffi ™ signal enhancement technology which has the potential to enhance the sensitivity of lateral flow immunoassays. In this paper, we demonstrate the increased sensitivity that can be achieved using this new signal enhancement technology, comparing it with traditional BSA blocking in a brain natriuretic peptide assay. The results show that this proprietary technology offers a 10-fold improvement in the limit of detection over the BSA-blocked control, highlighting its potential for enhancing both current and future lateral flow tests.
